Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLIOMA

Financiado

Cerrado

Molecular Mechanisms of Glioma Genesis and Progression

Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level... ver más

31/07/2014

FUNDACIO PRIVADA I...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

FUNDACIO PRIVADA INSTITUT D'...

0.00€ | Lider

FUNDACIO HOSPITAL UNIVERSITA...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-08629 CARACTERIZACION MOLECULAR DE LOS MECANISMOS IMPLICADOS EN LA... 73K€ Cerrado

BFU2017-82848-R ESTUDIO IN VIVO DE LAS FUNCIONES ANTAGONICAS DE OTX2/HOXA2 E... 85K€ Cerrado

MAMMAHOGLGR Understanding Hedgehog signalling in breast cancer and mamma... 179K€ Cerrado

tumourstemcells Molecular and cellular heterogeneity of tumour stem cells in... 201K€ Cerrado

H3.3CANCER The histone H3.3 variant in brain cancer pathogenesis 2M€ Cerrado

SAF2010-21729 ESTUDIO DE LA MUERTE CELULAR INDUCIDA POR LA MELATONINA EN C... 109K€ Cerrado

Líder del proyecto

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of glioma is essential for the development of successful and rational therapeutic strategies. Our project aims to: 1- Study the role of the TGF-beta, Shh, Notch, and Wnt signal transduction pathways in glioma. These pathways have been implicated in glioma but still not much is known about their specific mechanisms of action. 2- Study of a cell population within the tumour mass that has stem-cell-like characteristics, the glioma stem cells, and how the four mentioned pathways regulate their biology. 3- Study the role of a transcription factor, FoxG1, that has an important oncogenic role in some gliomas and that it is regulated by the four mentioned pathways interconnecting some of them. Our approach will be based on a tight collaboration with clinical researchers of our hospital and the study of patient-derived tumours. We will analyse human biopsies, generate primary cultures of human tumour cells, isolate the stem-cell-like population of patient-derived gliomas and generate mouse models for glioma based on the orthotopical inoculation of human glioma stem cells in the mouse brain to generate tumours with the same characteristics as the original human tumour. In addition, we will also study genetically modified mouse models and established cell lines. We expect that our results will help understand the biology of glioma and cancer, and we aspire to translate our discoveries to a more clinical ambit identifying molecular markers of diagnosis and prognosis, markers of response to therapies, and unveil new therapeutic targets against this deadly disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores